P102: In vitro antibody-dependent cellular cytotoxicity for prediction of breast cancer therapy response
FAU own research funding: EFI / IZKF / EAM ...
Start date : 15.08.2022
End date : 14.08.2023
Project details
Scientific Abstract
The standard of care treatment for HER2-positive breast cancer patients includes an anti-HER2-targeted antibody treatment. The antibody dependent cellular cytotoxicity (ADCC) is a key player associated with treatment response. Thus, the aim of the presented project is to conduct an ADCC biomarker assay in order to evaluate the association of ADCC capacity of peripheral blood mononuclear cells (PBMCs) with therapy response after neoadjuvant treatment with the trastuzumab-biosimilar ontruzant.
Involved:
Contributing FAU Organisations:
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
Department of Obstetrics and Gynaecology
Medizinische Fakultät
